336 PR from July
posted on
Oct 13, 2010 03:57AM
CARLSBAD, Calif. and CUPERTINO, Calif., July 27 /PRNewswire-FirstCall/ -- Patriot Scientific Corporation (OTC Bulletin Board:PTSC.ob - News), The TPL Group and Alliacense today announced their latest success in overcoming attempts to challenge the validity of the MMP Portfolio™. The United States Patent and Trademark Office (USPTO) has issued a Notice of Intent to Issue Reexamination Certificate for the US'336 patent indicating that all claims will be allowed with no amendments to the claim language. The US'336 patent, along with the entire MMP Portfolio™, enables technology that is essential for virtually all microprocessor-based products used today. Many companies have delayed their decision to purchase an MMP license on the basis of ongoing reexaminations with little regard for the risks of willful infringement and the escalating royalty rate structure of the MMP Portfolio™ Licensing Program. Today's announcement significantly increases those risks. This was the last of five reexamination requests to be successfully concluded on the US '336 over the past 3 years -- a process that involved the review of over 600 prior art references by the USPTO. This success follows a string of reexamination victories for the MMP patents, which include: "We have eagerly awaited the completion of the US'336 reexamination process," stated Carlton Johnson, chairman of the executive committee of Patriot's Board of Directors. "Not only have the majority of original claims in this patent survived, but it has been further strengthened by the addition of new claims. This represents an important victory for the MMP Portfolio." "This victory coupled with other reexam successes significantly strengthens the MMP Portfolio and magnifies the risk for those companies without a license to the technology," said Dan Leckrone, Chairman of The TPL Group, adding "an enormous amount of credit is due to the Alliacense team whose research, analysis, and strategy continues to be instrumental to our success." More than 75 global, market-leading companies from the US, Europe, Japan, Korea, Taiwan and China have licensed the MMP Portfolio™ technologies, resulting in over $300 million in licensing revenue. The MMP Portfolio has also been successful in litigation, with eight litigants purchasing licenses.MMP Portfolio Prevails In Latest Patent Reexamination